RU2706007C2 - Конденсированные бициклические соединения для лечения заболевания - Google Patents

Конденсированные бициклические соединения для лечения заболевания Download PDF

Info

Publication number
RU2706007C2
RU2706007C2 RU2017121588A RU2017121588A RU2706007C2 RU 2706007 C2 RU2706007 C2 RU 2706007C2 RU 2017121588 A RU2017121588 A RU 2017121588A RU 2017121588 A RU2017121588 A RU 2017121588A RU 2706007 C2 RU2706007 C2 RU 2706007C2
Authority
RU
Russia
Prior art keywords
optionally substituted
compound
formula
alkyl
alkylene
Prior art date
Application number
RU2017121588A
Other languages
English (en)
Russian (ru)
Other versions
RU2017121588A3 (enExample
RU2017121588A (ru
Inventor
Бенджамин Энтони ПРАТТ
Раджу Мохан
Original Assignee
Акарна Терапьютикс, Лтд.
Бенджамин Энтони ПРАТТ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акарна Терапьютикс, Лтд., Бенджамин Энтони ПРАТТ filed Critical Акарна Терапьютикс, Лтд.
Publication of RU2017121588A publication Critical patent/RU2017121588A/ru
Publication of RU2017121588A3 publication Critical patent/RU2017121588A3/ru
Application granted granted Critical
Publication of RU2706007C2 publication Critical patent/RU2706007C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017121588A 2014-11-21 2015-11-20 Конденсированные бициклические соединения для лечения заболевания RU2706007C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21
US62/083,031 2014-11-21
PCT/US2015/062017 WO2016081918A1 (en) 2014-11-21 2015-11-20 Fused bicyclic compounds for the treatment of disease

Publications (3)

Publication Number Publication Date
RU2017121588A RU2017121588A (ru) 2018-12-24
RU2017121588A3 RU2017121588A3 (enExample) 2019-05-21
RU2706007C2 true RU2706007C2 (ru) 2019-11-13

Family

ID=56014622

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017121588A RU2706007C2 (ru) 2014-11-21 2015-11-20 Конденсированные бициклические соединения для лечения заболевания

Country Status (17)

Country Link
US (5) US10233187B2 (enExample)
EP (1) EP3221321B1 (enExample)
JP (3) JP7224102B2 (enExample)
KR (1) KR20170117020A (enExample)
CN (2) CN107207513B (enExample)
AU (2) AU2015349687B2 (enExample)
CA (1) CA2968434A1 (enExample)
CL (1) CL2017001289A1 (enExample)
CO (1) CO2017005784A2 (enExample)
ES (1) ES2911293T3 (enExample)
IL (1) IL252309B (enExample)
MX (1) MX370480B (enExample)
MY (1) MY192927A (enExample)
RU (1) RU2706007C2 (enExample)
SA (1) SA517381566B1 (enExample)
SG (2) SG11201703953WA (enExample)
WO (1) WO2016081918A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
SG10201908881PA (en) * 2015-03-26 2019-11-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
KR20190040936A (ko) * 2016-05-25 2019-04-19 아카나 테라퓨틱스, 엘티디. 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
TW201910332A (zh) * 2017-06-02 2019-03-16 英商艾卡那治療有限公司 稠合的雙環化合物
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
EP4003350A1 (en) 2019-07-23 2022-06-01 Novartis AG Treatment comprising fxr agonists
CA3142905A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
US20220340668A1 (en) 2019-09-03 2022-10-27 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Fxrアゴニストの使用を含む処置
JP2023507364A (ja) 2019-12-20 2023-02-22 ノバルティス アーゲー インテグリン阻害剤を使用する肝疾患の治療の組み合わせ
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
TW202227405A (zh) * 2020-08-24 2022-07-16 以色列商安道麥馬克西姆有限公司 用於製備經取代的吡唑之方法
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
RU2423363C2 (ru) * 2003-12-02 2011-07-10 Экселиксис, Инк. Производные азепиноиндола в качестве фармацевтических средств

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003150A (es) 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
WO2010036362A1 (en) 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患治療用の縮合二環式化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015746A1 (en) * 2003-07-23 2007-01-18 X-Ceptor Therapeutics Inc. Azepine derivaties as pharmaceutical agents
RU2423363C2 (ru) * 2003-12-02 2011-07-10 Экселиксис, Инк. Производные азепиноиндола в качестве фармацевтических средств
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARINOZZI MAURA et al., "Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoic X Receptor (FXR) agonists", Bioorganic and Medicinal Chemistry, 2012, vol. 20, pages 3429-3445. *

Also Published As

Publication number Publication date
US10233187B2 (en) 2019-03-19
US20190308977A1 (en) 2019-10-10
IL252309A0 (en) 2017-07-31
CO2017005784A2 (es) 2017-10-31
CN111662297A (zh) 2020-09-15
CL2017001289A1 (es) 2018-03-02
IL252309B (en) 2021-01-31
EP3221321A4 (en) 2018-04-25
JP7224102B2 (ja) 2023-02-17
AU2015349687B2 (en) 2020-07-09
RU2017121588A3 (enExample) 2019-05-21
US20230183247A1 (en) 2023-06-15
AU2020250270A1 (en) 2020-11-05
SG11201703953WA (en) 2017-06-29
US20210147426A1 (en) 2021-05-20
JP2023011731A (ja) 2023-01-24
CA2968434A1 (en) 2016-05-26
KR20170117020A (ko) 2017-10-20
JP2021011482A (ja) 2021-02-04
SG10202010386PA (en) 2020-11-27
MX2017006694A (es) 2018-03-16
SA517381566B1 (ar) 2021-05-16
EP3221321A1 (en) 2017-09-27
WO2016081918A1 (en) 2016-05-26
EP3221321B1 (en) 2021-12-15
ES2911293T3 (es) 2022-05-18
RU2017121588A (ru) 2018-12-24
JP2017535614A (ja) 2017-11-30
US20250171446A1 (en) 2025-05-29
MX370480B (es) 2019-12-16
AU2020250270B2 (en) 2022-08-25
CN107207513A (zh) 2017-09-26
CN107207513B (zh) 2020-07-28
MY192927A (en) 2022-09-15
BR112017010627A2 (pt) 2018-02-14
HK1244802A1 (zh) 2018-08-17
US20170355699A1 (en) 2017-12-14
AU2015349687A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
RU2706007C2 (ru) Конденсированные бициклические соединения для лечения заболевания
JP7089566B2 (ja) 疾患の処置のための縮合二環式化合物
JP6843061B2 (ja) 疾患治療のための縮合二環化合物
JP2019520335A (ja) 疾患治療用の縮合二環式化合物
HK1244802B (en) Fused bicyclic compounds for the treatment of disease
HK1245795B (en) Fused bicyclic compounds for the treatment of disease
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
BR112017010627B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos